Correlação entre achados de biópsia pulmonar cirúrgica e de autópsia e dados clínicos em pacientes com infiltrados pulmonares difusos e insuficiência respiratória aguda by Canzian, Mauro et al.
425
CLINICS 2006;61(5):425-32
aDivisions of Respiratory Diseases and Pathology, Heart Institute (InCor),
São Paulo University Medical School - São Paulo/SP, Brazil.
bDepartment of Pathology, Hospital das Clínicas, São Paulo University
Medical School – São Paulo/SP, Brazil.
cDepartment of Biostatistics, Federal University of São Paulo/São Paulo/SP,
Brazil.
Email: vcapelozzi@lim05.fm.usp.br
Received for publication on June 13, 2006.
Accepted for publication on June 27, 2006.
CLINICAL SCIENCES
CORRELATION BETWEEN SURGICAL LUNG BIOPSY
AND AUTOPSY FINDINGS AND CLINICAL DATA IN
PATIENTS WITH DIFFUSE PULMONARY INFILTRATES
AND ACUTE RESPIRATORY FAILURE
Mauro Canziana, Alexandre de Matos Soeirob, Marcel Frederico de Lima Tagac,
Carmen Silvia Valente Barbasa, Vera Luiza Capelozzib
Canzian M, Soeiro A de M, Taga MF de L, Barbas CSV, Capelozzi VL. Correlation between surgical lung biopsy and
autopsy findings and clinical data in patients with diffuse pulmonary infiltrates and acute respiratory failure. CLINICS.
2006(5):425-32.
INTRODUCTION: Surgical lung biopsy is an invasive procedure performed when other procedures have failed to provide an
urgent and specific diagnosis, but there may be reluctance to perform it in critically ill patients with diffuse pulmonary infiltrates.
PURPOSE: To evaluate the diagnostic accuracy, the changes in therapy and survival of patients with diffuse lung infiltrates,
mostly presenting acute respiratory failure, who underwent surgical biopsy.
METHODS: We retrospectively examined medical records and surgical lung biopsies from 1982 to 2003 of 63 patients older than
18 years with diffuse infiltrates. Clinical diagnoses were compared to histopathological ones, from biopsies and autopsies. Laboratory
and epidemiological data were evaluated, and their relationship to hospital survival was analyzed.
RESULTS: All histological specimens exhibited abnormalities, mostly presenting benign/inflammatory etiologies. Fifteen patients
had an etiologic factor determined in biopsy, most commonly Mycobacterium tuberculosis. The preoperative diagnosis was
rectified in 37 patients. Autopsies were obtained in 25 patients and confirmed biopsy results in 72% of cases. Therapy was
changed for 65% of patients based on biopsy results. Forty-nine percent of patients survived to be discharged from the hospital.
Characteristics that differed significantly between survivors and nonsurvivors included sex (P = 0.05), presence of comorbidity (P
= 0.05), SpO2 (P = 0.05), and presence of diffuse alveolar damage in the biopsy (P = 0.004).
CONCLUSION: Surgical lung biopsy provided a specific, accurate etiologic diagnosis in many patients with diffuse pulmonary
infiltrates when clinical improvement did not occur after standard treatment. Surgical lung biopsy may reveal a specific diagnosis
that requires distinct treatment, and it would probably have an impact in lowering the mortality of these patients.
KEYWORDS: Surgical lung biopsy. Diffuse pulmonary infiltrate. Acute respiratory failure. Diffuse alveolar damage. Autopsy.
INTRODUCTION
Surgical lung biopsy (SLB) is an invasive procedure
performed to assist in treatment efforts when other
noninvasive or minimally invasive procedures have failed
to provide an urgent and specific diagnosis.1,2 Surgical lung
biopsy is performed through a limited thoracotomy, with-
out costal arc resection, allowing tissue samples to be ob-
tained from 1 or more involved lobe(s)1 for adequate his-
tological, histochemical, and molecular analysis. However,
there may be reluctance to perform SLB in critically ill pa-
tients with diffuse pulmonary infiltrates, who are frequently
suffering from acute respiratory failure, often undergoing
mechanical ventilation, and hemodynamically unstable.
The progression of the disease and the need of a specific
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diagnosis are decisive factors. The purpose of this study
was to evaluate diagnostic accuracy, changes in therapy, and
survival of patients with diffuse lung infiltrates, mostly pre-
senting acute respiratory failure, who underwent SLB.
METHOD
Patients. We examined the medical records of all pa-
tients who underwent SLB at our institutions from Janu-
ary 1982 to December 2003. From these we selected pa-
tients older than 18 years of age with diffuse infiltrates on
chest roentgenogram and respiratory failure. Respiratory
failure was defined as a PaO2 of less than 60 mmHg
(hypoxemic ARF), or a SpO2 less than 90% of arterial
blood, or PaCO2 more than 50 mm Hg (hypercapnic acute
respiratory failure) while breathing room air. Acute was
defined as onset of symptoms of respiratory distress less
than 10 days prior to SLB, in order to exclude those pa-
tients with a steady deterioration of a chronic process. Sur-
gical lung biopsy was performed at the discretion of the
attending physician under general anesthesia; progressive
hypoxemia was the usual indication. Through a limited tho-
racotomy, tissue samples were removed with a cutting sta-
pler. A specific protocol for specimen processing was fol-
lowed. A portion of the surgical specimen was sent to sur-
gical pathology, and permanent sections were examined
after appropriate staining. The remaining specimen was sent
to the microbiology laboratory where smears were prepared
and part of the tissue was homogenized. Cultures were pre-
pared for aerobic and anaerobic bacteria, fungi, mycobac-
teria, Legionella, Nocardia, Chlamydia, and viruses. Stains
were performed with Gram stain for bacteria, Grocott for
fungi and Pneumocystis carinii, and Ziehl-Neelsen for my-
cobacteria and Nocardia. Results of stains were usually
available within 3 hours after specimen arrival in the labo-
ratory.
Statistical Analysis. Comparisons between groups were
made using chi-square analysis and unpaired t test when
appropriate; P < 0.05 was taken as significant. Every analy-
sis was performed with the SPSS for Windows 10.0 statis-
tical software.
RESULTS
Patient Characteristics. Over the period examined, 303
surgical lung biopsies were performed, and 63 cases
(20.8%) met our study criteria. Thirty-one patients (49%)
were women and 32 (51%) were men, with a median age
of 51 years (range, 18 to 92 years). Arterial blood samples
for gas analysis taken during inspiration of room air in the
24 hours preceding SLB were obtained from 56 patients
(89%). Forty-four patients were in acute respiratory fail-
ure as indicated by the following: 38 of them had a PaO2
< 60 mm Hg; 4 had a PaCO2 > 50 mm Hg; and in 2 pa-
tients, both PaO2 and PaCO2 indices were altered. Eleven
cases had only SpO2 values (under 90%) available. Tables
1 and 2 list respectively the gasometric data and preexist-
ing medical conditions in the study population. Thirty-three
patients (52%) were immunocompromised, and 48 (66%)
had preexisting medical conditions. The mean time from
admission to SLB was 18 days (range, 0 to 61 days), the
mean interval from SLB to hospital discharge or death was
21 days (range, 1 to 143 days) and the mean total hospi-
talization time was 39 days (range, 4 to 184 days).
Diagnostic Results. The diagnostic results of SLB are
shown in Table 3. All biopsy specimens exhibited abnor-
malities. Forty-eight patients (76%) had benign/inflamma-
tory etiologies; 14% had infectious causes, and 10% had
infiltrates directly or indirectly due to neoplastic process.
Among the main benign/inflammatory etiologies, 26 pa-
tients (41.3%) had diffuse alveolar damage (DAD)—as the
only histopathological diagnosis in 7 patients, or associ-
ated with the main process in 19 patients. Twenty one of
these were in the exudative stage and 5 in the proliferative
stage. Acute lung injury was observed in 6 cases. At least
15 patients received steroid treatment, but in only 3 cases
was corticotherapy started after the histopathological re-
sult (Table 4). Only 1 patient was in acute respiratory dis-
tress clinically. Seven patients (11%) had usual interstitial
pneumonia (UIP), and 7 patients had chronic bronchioli-
tis, both in acute exacerbation and discordant radiology vs
histopathology. Seven patients (11%) had a granulomatous
process (2 sarcoidosis and 5 tuberculosis); 5 patients (8%)
had pulmonary thromboembolism, and 4 patients (6.3%)
had passive congestion. For 15 patients (23%) an etiologic
factor was determined through the biopsy as follows: acute
and chronic broncho-aspiration in 4 patients (6.3%) and
infectious etiologic factor in 11 patients (17%). The most
common cause found was tuberculosis, occurring in 5 pa-
tients (8%), followed by cytomegalovirus in 2 patients
(3%), Pneumocystis carinii in 2 patients (3%), Strongy-
loides sp. in 1 patient (1%), and Aspergillus sp. in 1 pa-
tient (1%). Clinical, biopsy, and necropsy diagnoses were
compared (Table 3). In this situation, the preoperative di-
agnosis of the cause of respiratory failure or diffuse pul-
monary infiltrate was changed in 37 patients (59%). Au-
topsies were obtained in 25 patients who died in hospital
and confirmed SLB results in 18 cases (72%). Therapy was
changed in 31 patients (65%) based on SLB results. Change
in therapy was defined as the as the addition or subtrac-
tion of 1 or more drugs or the early discontinuation of ag-
gressive life support. Drug changes usually involved anti-
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Table 1 - Gasometric data of the 63 patients studied, previous to surgical lung biopsy
Case pH PaO2 PaCO2 SpO2 Fi O2 Case pH PaO2 PaCO2 SpO2 Fi O2
1 7,36 100 30 97 60 33 7,48 57 36 92 NA
2 7,08 73 70 90 95 34 7,43 44,5 44,8 82,4 NA
3 7,45 33 35 59,9 NA 35 NA NA NA 87 NA
4 7,31 56 31 85,6 60 36 NA NA NA 88 NA
5 7,39 66 44,9 92,9 NA 37 NA NA NA NA NA
6 NA NA NA 80 NA 38 7,42 30,9 28,4 59,6 NA
7 7,38 51,8 42 85 NA 39 7,28 48,1 29 76,2 NA
8 NA NA NA 88 NA 40 NA NA NA 96 60
9 7,36 120 36 96,3 60 41 7,42 50,6 34,7 86,2 50
10 7,43 NA 50,1 86,9 100 42 NA NA NA NA NA
11 7,46 51 28,6 86 NA 43 7,42 52 25 88,3 60
12 7,22 57,9 62,4 88,2 45 44 7,43 51,1 36,8 84 NA
13 7,39 58,2 40,3 89,6 NA 45 7,46 59,5 37 92 NA
14 7,43 125,9 19,5 98,8 40 46 7,33 47 46,5 79,5 NA
15 7,44 45,3 27,5 82,5 NA 47 7,03 49 87 63,1 40
16 7,5 46,3 29 86,7 100 48 NA NA NA 90 NA
17 7,35 29 40 49,1 NA 49 7,13 65 63 85,8 100
18 NA NA NA NA NA 50 NA NA NA 96 NA
19 NA NA NA 87 NA 51 NA NA NA NA NA
20 7,51 48,3 26,3 88,4 60 52 7,37 42,8 23,5 75,7 NA
21 7,56 67 25 95,6 NA 53 7,47 59,8 29,6 92,4 NA
22 NA NA NA 83 NA 54 7,36 40 46 72 NA
23 7,37 54 40,7 86,6 NA 55 NA NA NA NA NA
24 NA NA NA 68 100 56 7,44 38,9 33,8 75,8 50
25 7,42 80 27 96,2 NA 57 NA NA NA 80 NA
26 7,48 43 29 80 60 58 NA NA NA NA NA
27 NA NA NA NA NA 59 7,49 87,1 23,9 97,3 NA
28 7,4 27,2 37,2 49,9 80 60 7,49 45,2 37,2 85 NA
29 7,43 71,7 32,1 94,6 NA 61 7,1 79 54 88 40
30 7,41 36,5 42,5 70,1 NA 62 7,23 105,9 20,4 96,3 40
31 NA 41,5 33 77,5 NA 63 7,43 52,2 38 87,8 NA
32 7,44 35,5 38 70,8 40
NA: data non-available
Note: Data concerning PaO2 and PaCO2  expressed in mmHg; data concerning SpO2 an FiO2 expressed in percentage.
biotics and/or corticosteroids, but also included heparini-
zation and the initiation or discontinuation of antineoplas-
tic agents for malignancy or drug-induced toxicity, respec-
tively. Surgical complication data was obtained in 32 pa-
tients; surgical complications were present in 5 patients (1
infection of the surgical wound, 1 pneumothorax, and 3
subcutaneous emphysema, Table 4).
Survival. Thirty-one patients (49%) survived to be dis-
charged from the hospital.. For the 34 patients who died
in hospital, survival time after SLB was 20 ± 29 days. Al-
though not statistically significant, alterations in therapy
resulting from SLB modified the survival rate in 7 patients
(22%) out of 32 patients who had the information avail-
able (X2 = 0.14, P = 0.4). A marginal significance was
found between mortality and the presence of surgical com-
plications (X2 = 3.80, P = 0.05). In addition, neither the
availability of a specific diagnosis nor changes in diagno-
sis, as well as infectious agent or immunocompromised sta-
tus affected survival rates (X2 = 0.44, P = 0.24; X2 = 0.51,
P = 0.27; and X2 = 0.13, P = 0.08, respectively).
Preoperative characteristics that did not differ between
survivors and nonsurvivors included age (X2 = 2.42 ; P =
0.9.), PaO2, (X2 = 5.07 ; P = 0.1) PCO2, (X2 = 4.02; P =
0.1) and breathing frequency at the time of SLB ((X2 =
1.37; P = 0.6). There was no difference between the
preoperative primary diagnosis and the diagnosis found at
SLB in survivors versus nonsurvivors. Characteristics that
differed significantly between survivors and nonsurvivors
included sex (X2 = 3.56 ; P = 0.05), comorbidity (X2 = 3.56
; P = 0.05), SpO2 (X2 =3.98 ; P = 0.05), and presence of
DAD in the SLB (X2 = 8.38 ; P = 0.004). Eight out of 26
patients (31%) with DAD and only 3 out of 11 patients (27
%) with infectious etiology survived, in contrast to the case
with acute exacerbation of UIP, in which 4 of 7 patients
(57%) survived. A marginal significance was obtained for
the clinical and gasometric pattern of acute respiratory fail-
ure (X2 =3.1; P = 0.07)
DISCUSSION
Although SLB did provide a specific diagnosis in many
patients with diffuse pulmonary infiltrates and acute res-
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Table 2 - Epidemiological data of the 63 patients studied
Case Sex Age Total Hospitalization Underlying disease Presence of Outcome
Time (days) immunossupression factor
1 m 56 20 No No Dead
2 m 48 32 No No Dead
3 m 76 60 Renal and heart failure No Survived
4 f 19 47 BMT (aplastic anemia) Yes Dead
5 m 67 44 No No Survived
6 m 55 17 Rheumatologic disease NOS No Dead
7 f 52 27 Heart failure No Survived
8 m 48 55 Crohn’s disease+ renal failure No Dead
9 m 66 42 Rheumatoid arthritis No Dead
10 f 37 44 SLE No Dead
11 m 34 16 AIDS Yes Dead
12 m 45 18 CML Yes Dead
13 m 52 20 No No Survived
14 f 21 38 Non-Hodgkin’s lymphoma Yes Survived
15 f 30 37 No No Survived
16 f 63 9 Carcinomatosis Yes Dead
17 m 37 48 No No Dead
18 f 51 22 Gastroesophageal reflux No Survived
19 m 52 38 Liver cirrhosis No Survived
20 f 46 26 Adenocarcinoma NOS No Dead
21 f 34 4 CML Yes Dead
22 f 49 19 Carcinomatosis Yes Survived
23 m 23 21 Burns No Dead
24 m 58 13 Adenocarcinoma NOS Yes Dead
25 m 77 45 COPD Yes Dead
26 m 36 20 BMT Yes Dead
27 m 78 17 No Yes Survived
28 f 54 9 SLE No Dead
29 f 51 184 Wegener’s granumatosis No Dead
30 m 57 33 Ischemic myocardiopathy No Dead
31 f 21 42 SLE No Survived
32 f 74 16 Congestive myocardiopathy No Dead
33 m 55 91 Congestive myocardiopathy No Dead
34 m 65 69 Sarcoidosis No Dead
35 f 46 15 Wegener’s granumatosis No Survived
36 f 52 76 No Yes Survived
37 f 92 24 Ischemic myocardiopathy No Survived
38 f 26 27 BMT (CML) Yes Dead
39 f 53 98 Rheumatoid arthritis No Dead
40 m 70 47 Non-Hodgkin’s lymphoma Yes Dead
41 f 30 65 Colitis NOS No Survived
42 f 82 22 Neoplasia NOS Yes Survived
43 f 50 91 SLE Yes Survived
44 m 57 38 Gastroesophageal reflux+DM 2 No Survived
45 m 65 37 Ischemic myocardiopathy+DM 2 No Dead
46 m 47 37 ALL Yes Dead
47 m 32 16 ALL Yes Dead
48 f 68 37 Hypertension No Survived
49 m 53 26 Heart transplantation Yes Dead
50 m 22 89 ALL Yes Survived
51 m 18 7 BMT (ALL) Yes Survived
52 f 76 36 Ischemic myocardiopathy No Dead
53 f 55 17 Carcinomatosis Yes Dead
54 f 25 47 No No Survived
55 f 38 42 No No Dead
56 m 37 84 CML Yes Dead
57 f 36 10 Ischemic myocardiopathy No Survived
58 f 36 14 Carcinomatosis Yes Survived
59 m 73 34 No No Survived
60 f 52 36 No No Survived
61 m 31 49 SLE No Dead
62 m 28 48 Aplastic anemia Yes Dead
63 f 73 37 No No Survived
Abbreviations: AIDS:  Acquired Immunodeficiency Syndrome; ALL: Acute Lymphocytic Leukemia; BMT: Bone Marrow Transplantation; CML: Chronic
Myelocytic Leukemia; CPOD: Chronic Obstructive Lung Disease;  DM: Diabetes Mellitus; NOS: no other specification; SLE: Systemic Lupus Erythematous
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Table 3 - Distribution of clinical, biopsy and necropsy
diagnoses
Diagnoses Clinical Biopsy Necropsy
Infectious lung 22 (35) 9 (14) 9 (38)
disease
Granulomatous 7 (11) 7 (11) 1 (4)
lung disease
Airway diseases 4 (6) 10 (16) 1 (4)
Interstitial pneumonia 11 (17) 10 (16) 1 (4)
Circulatory disturbance 6 (10) 7 (11) 2 (8)
Carcinoma 6 (10) 5 (8) 3 (13)
Hypersensitivity 2 (3)
pneumonia
Diffuse alveolar 7 (11) 6 (25)
damage
Capilaritis/ vasculitis 5 (8) 4 (6) 1 (4)
Amyloidosis 1 (2)
Histiocytosis X 1 (2)
Lymphoma 1 (2) 1 (2)
Total 63 (100) 63 (100) 24 (100)
piratory failure, the hospital mortality rate of 51% was high
in this hypoxic patient population. Hospital mortality rates
from similar but smaller series of hypoxic patients under-
going SLB are consistent with our experience, ranging from
50% to 70%.3-7 In contrast, reported mortality rates for all
patients (hypoxic and nonhypoxic) undergoing SLB tend
to be lower.4, 8-10 Greenman and coworkers11 found a 73%
mortality rate in hypoxic (PaO2 < 55 mm Hg)
immunosuppressed patients and a 39% mortality rate in
nonhypoxic patients. In immunosuppressed patients, Jaffe
and Maki12 found a significantly higher PaO2 in survivors
of SLB, as compared to nonsurvivors. While our study was
not designed to evaluate hypoxia as a predictor of mortal-
ity in patients undergoing SLB, probably our hypoxic pa-
tients ultimately did not fare well.
Given the high mortality rate, it would be helpful to be
able to predict outcome. Poe and coworkers13 in a retro-
spective review attempted to predict mortality in
immunocompromised patients with pulmonary infiltrates
undergoing either transbronchial biopsy or SLB. They
found that early mechanical ventilation (within the first 72
hours of admission, either preoperatively or for more than
24 hours postoperatively), the initial room-air PaO2 , and
corticosteroid therapy at the onset of symptoms were sig-
nificant predictors of mortality. None of the 51 patients who
simultaneously had a PaO2 of < 50 mm Hg on room air,
was receiving corticosteroids, and required early mechani-
cal ventilation survived.
Most investigators feel that mortality in patients under-
going SLB is due to the severity of the underlying disease
and not to complications of the surgical procedure.3,4,14-16
With the exception of a mortality percentage of 21.4% re-
ported by Ferson et al,17 more recent series refer indices
lower than 8% directly related to the biopsy procedure.18-
21
 While this assertion is difficult to prove, the complica-
tions in our series did not appear to directly cause death.
However, the mortality rate in the patients suffering com-
plications, while marginally significant, suggests that such
complications requires more complex patient care. Stud-
ies evaluating the impact of SLB complications on outcome
should include a nonoperative control group. In a prospec-
tive, randomized study comparing SLB and empiric anti-
biotic therapy for acute pneumonitis in 22 non-neutropenic
cancer patients, Potter and coworkers22 did not find a sig-
nificant difference in mortality rates between the 2 groups.
The investigators did feel that 3 patients (21% of those un-
dergoing SLB) experienced complications of SLB that con-
tributed directly to their deaths. Although our patients did
not suffer this high rate of catastrophic complications, any
complication of a procedure of uncertain benefit is of
concern.
Intrathoracic surgery, especially in the hypoxic patient,
carries with it the risk of prolonged postoperative mechani-
cal ventilation. Although it became possible to extubate half
of our patients postoperatively, 6 patients (50%) were me-
chanically ventilated until death. It is not known how many
of these patients would have eventually required ventilatory
support had SLB not been performed, although only 1 of
the patients presented a serious complication (air leak) re-
lated to the biopsy.
In the last decades, advances in technology such as
computerized tomography, acquisition of knowledge in lung
pathology produced by indications of surgical lung biopsy,
the new ATS/ERS Classification of the Interstitial Lung
Diseases may be an explanation for our 100% of specificity
in diagnosis, in contrast to those found in previous series
of SLB in immunosuppressed patients, ranging from 40%
to 83%.11,12,23-27 Autopsy results in 18 (72%) patients veri-
fied the accuracy of SLB in all but 7 cases; the additional
diagnosis (4 infectious pneumonias, 5 diffuse alveolar dam-
ages, and 1 bronchiolitis) may represent infections or com-
plications resulting from them, which occurred between
SLB and death. In many patients, the preoperative diag-
nosis was either erroneous or incomplete. The impact of
SLB on changes in diagnoses, the presence of a specific
diagnosis, and subsequent alterations in therapy on survival
were very encouraging, and mirrored the experience of
many others investigators.7,14,16,28,29 Delays in diagnosis can
account for the high mortality rate reported in the litera-
ture,25,28,30 because the study population included many pa-
tients undergoing SLB relatively late in the course of their
acute respiratory failure. Mortality might have been even
greater in the diagnostic group, had a diagnosis not been
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Table 4 - Data concerning complications related to biopsy procedure, change in therapy after histopathological results and
corticotherapy before and after histopathological results
Case Complications Diffuse alveolar damage Change in therapy Corticotherapy Corticotherapy
pre-biopsy post-biopsy
1 no yes (exs) yes yes yes
2 no yes (exs) yes no no
3 no yes (pro) yes no no
4 NA no NA NA NA
5 no no NA yes NA
6 no yes (exs) no# no no
7 no no yes no yes
8 no yes (exs) yes no no
9 yes* no yes yes yes
10 no yes (pro) yes yes yes
11 no yes (exs) yes yes yes
12 no yes (exs) yes no no
13 NA no NA NA NA
14 yes** no yes yes yes
15 no no yes no no
16 NA no NA NA NA
17 no no yes no no
18 NA yes (exs) NA NA NA
19 no yes (exs) yes no yes
20 NA yes (exs) NA NA NA
21 no no no# no NA
22 no yes (pro) yes no no
23 no no no no no
24 NA yes (exs) NA NA NA
25 no no yes no no
26 NA yes (exs) NA NA NA
27 NA no NA NA NA
28 no yes (exs) no# yes yes
29 no no yes no yes
30 no no No no no
31 NA no NA NA NA
32 no yes (pro) no# yes yes
33 no no No no no
34 no no yes no no
35 NA no NA NA NA
36 NA no NA NA NA
37 NA no NA NA NA
38 NA yes (pro) NA NA NA
39 no no yes yes no
40 yes*** yes (exs) No yes yes
41 NA no NA NA NA
42 no no No yes yes
43 NA no NA NA NA
44 NA no NA NA NA
45 NA yes (exs) NA NA NA
46 NA no NA NA NA
47 NA no NA NA NA
48 yes*** yes (exs) No yes yes
49 no yes (exs) Yes yes yes
50 yes*** no No no no
51 NA no NA NA NA
52 NA no NA NA NA
53 NA no NA NA NA
54 no yes (exs) No no no
55 NA yes (exs) NA NA NA
56 NA yes (exs) NA NA NA
57 NA no NA NA NA
58 NA no NA NA NA
59 NA yes (exs) NA NA NA
60 NA no NA NA NA
61 NA no NA NA NA
62 NA no NA NA NA
63 NA yes (exs) NA NA NA
NA: data non-available; *  Infection of surgical wound; **  Atelectasia and pneumothorax; *** Subcutaneous emphysema; # Death before histopathological
conclusion; “exs”: exsudative phase; “pro”: proliferative phase
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made, this being a speculation that can be evaluated using
our data. Also, patients without a specific diagnosis may
have had less severe disease and may have thus been
preselected for lower mortality. Nevertheless, while SLB
is undoubtedly of value in securing or confirming diag-
noses, our results suggest that SLB may influence patient
survival rates through the direction of treatment strategy.
If patient benefit is defined by survival, the 6 patients
(50% of total) who both survived and in whom SLB re-
sults were judged to be useful in guiding therapy can defi-
nitely be described as having benefited from SLB.
In conclusion, SLB provided a specific, accurate
etiologic diagnosis in many patients with diffuse pulmo-
nary infiltrates and acute respiratory failure when clinical
improvement did not occur after standard treatment. Sur-
gical lung biopsy may produce a specific diagnosis that in-
dicates a distinct treatment, lowering patient mortality.
RESUMO
Canzian M, Soeiro A de M, Taga MF de L, Barbas CSV,
Capelozzi VL. Correlação entre achados de biópsia pulmo-
nar cirúrgica e de autópsia e dados clínicos em pacientes
com infiltrados pulmonares difusos e insuficiência respi-
ratória aguda. CLINICS. 2006(5):425-32.
INTRODUÇÃO: A biópsia pulmonar cirúrgica é um pro-
cedimento invasivo executado quando outros procedimentos
não forneceram um diagnóstico urgente e específico; no en-
tanto, pode haver relutância em sua execução em pacientes
críticos, que apresentam infiltrados pulmonares difusos.
OBJETIVO: Avaliar a acurácia diagnóstica, mudanças na
terapêutica e a sobrevida de pacientes com infiltrado pul-
monar difuso, em sua maior parte apresentando a insufici-
ência respiratória aguda, submetidos a biópsia cirúrgica.
MÉTODO: Foram examinados retrospectivamente regis-
tros médicos e biópsias pulmonares cirúrgicas de 63 paci-
entes maiores de 18 anos de idade, com infiltrados difusos,
entre 1982 a 2003. Os diagnósticos clínicos foram compa-
rados aos histopatológicos, de biópsias e de autópsias. Da-
dos laboratoriais e epidemiológicos foram avaliados e sua
correlação com a sobrevida hospitalar analisada.
RESULTADOS: Todos os espécimes histológicos exibiram
alterações, em sua maior parte de natureza benigna/infla-
matória. Em quinze casos o fator etiológico pôde ser de-
terminado na biópsia, sendo o Mycobacterium tuberculosis
o mais freqüente. O diagnóstico pré-operatório foi muda-
do em 37 pacientes. Autópsias foram realizadas em 25 pa-
cientes e confirmaram resultados da biópsia em 72%. A te-
rapêutica foi alterada em 65% dos pacientes com base nos
resultados da biópsia. Quarenta e nove por cento dos paci-
entes sobreviveram ao final do período de hospitalização.
Características que diferiram significativamente entre so-
breviventes versus não sobreviventes incluíram sexo
(p=0.05), a presença de comorbidade (p=0.05), a SatO2
(p=0.05), e a presença de dano alveolar difuso na biópsia
(p=0.004).
CONCLUSÃO: A biópsia pulmonar cirúrgica forneceu um
diagnóstico etiológico específico e exato em muitos paci-
entes com infiltrados pulmonares difusos quando a melhora
clínica não ocorreu após o tratamento padrão. A biópsia
pulmonar cirúrgica pode fornecer diagnósticos que reque-
rem tratamentos específicos, com provável impacto na re-
dução do índice de mortalidade destes pacientes.
UNITERMOS: Biópsia pulmonar cirúrgica. Infiltrado pul-
monar difuso. Insuficiência respiratória aguda. Dano
alveolar difuso. Autópsia.
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